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Abstract
Gaucher’s disease (GD) is characterized by loss of lysosomal glucocerebrosidase (GC) activity. Mutations in the gene
encoding GC destabilize the protein’s native folding leading to ER-associated degradation (ERAD) of the misfolded enzyme.
Enhancing the cellular folding capacity by remodeling the proteostasis network promotes native folding and lysosomal
activity of mutated GC variants. However, proteostasis modulators reported so far, including ERAD inhibitors, trigger cellular
stress and lead to induction of apoptosis. We show herein that lacidipine, an L-type Ca2+ channel blocker that also inhibits
ryanodine receptors on the ER membrane, enhances folding, trafficking and lysosomal activity of the most severely
destabilized GC variant achieved via ERAD inhibition in fibroblasts derived from patients with GD. Interestingly,
reprogramming the proteostasis network by combining modulation of Ca2+ homeostasis and ERAD inhibition remodels the
unfolded protein response and dramatically lowers apoptosis induction typically associated with ERAD inhibition.
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Introduction
Lysosomal storage disorders (LSD) are a group of more than 40
clinically distinct inherited diseases characterized by the deficiency
of essential lysosomal hydrolytic functions [1]. Gaucher’s disease
(GD), the most common LSD, is caused by loss of lysosomal
glucocerebrosidase (GC) activity and consequent accumulation of
the GC substrate, glucosylceramide [2].
The most frequently encountered mutations in the GC
encoding gene (GBA; [3]) do not directly affect the enzyme’s
activity but destabilize its native structure [4]. They are typically
single amino acid substitutions that impair the enzyme’s folding
causing retro-translocation of misfolded GC to the cytoplasm for
ER-associated degradation (ERAD) and, consequently, leading to
deficiency of lysosomal GC activity [5]. The L444P substitution is
one of the most frequently occurring misfolding mutations [4]. It
severely destabilizes GC native structure and results in complete
loss of activity [6]. GD patients who are homozygous for the
L444P GC allele typically present severe neuropathic symptoms
[6].
Interestingly, a number of unstable GC variants containing
misfolding mutations (including L444P GC) can traffic to the
lysosome and retain catalytic function if forced to fold into their
native 3D structure [7–10]. Chemical chaperones, small molecules
that rescue the native folding of mutated GC enabling lysosomal
trafficking and enhancing enzyme activity were recently reported
[8]. However, chemical chaperones are highly mutation-specific
[11] and rarely proved effective to rescue GC variants associated
with neuropathic manifestations of the disease [12]. Modulation of
the proteostasis network has been explored recently to restore the
activity of GC variants in cells derived from GD patients with
neuropathic symptoms [10,13–15]. The ultimate goal of this
approach is to achieve chemically induced enhancement of the
innate cellular folding capacity – a strategy that could be in
principle applicable to rescue the function of a large class of
mutated enzymes processed through the secretory pathway [10].
However, the mechanism of action of most small molecules
reported to function as proteostasis modulators thus far relies on
induction of cellular stress, and, particularly, activation of the
unfolded protein response (UPR). Sustained UPR activation, in
turn, leads to induction of apoptosis [13,14]; hence the recent
focus on modulating the cellular folding capacity to rescue the
folding of unstable, degradation-prone proteins without causing
induction of the apoptotic cascade [13,14].
Native folding of GC variants is limited by rapid disposal of
unstable folding intermediates via ERAD [5]. We previously
reported that chemical inhibition of specific steps of the ERAD
pathway enables rescue of folding and trafficking of mutated GC
[15]. Particularly, administration of Eeryastatin I (EerI), a small
molecule that blocks retrotranslocation of misfolded substrates to
the cytoplasm [16,17], resulted in dramatic rescue of folding and
lysosomal activity of multiple GC variants. ERAD inhibition via
EerI treatment was shown to prolong ER retention of mutated
GC, thereby enhancing the pool of GC folding intermediates
amenable to folding rescue. However, EerI treatment was also
observed to cause dramatic induction of UPR and apoptosis [15].
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Accumulation of the GC substrate (glucosylceramide) in GD
cells causes excessive [Ca2+]ER efflux through the ryanodine
receptors (RyRs) [18–20]. Because maintenance of intracellular
Ca2+ homeostasis is essential for a number of fundamental cellular
activities including protein folding in the ER [21,22], impairment
of intracellular Ca2+ homeostasis in GD cells is likely to hamper
the folding of unstable GC variants [13,23]. Re-establishing the
cellular gradient of [Ca2+] in GD fibroblasts was shown to create
an ER environment more amenable to native folding of GC
variants [13,14]. Lowered [Ca2+] in the cytosol observed upon
treatment of GD cells with lacidipine, a small molecule that
inhibits both RyRs on the ER membrane and L-type Ca2+
channels (LTCC) on the plasma membrane [24,25], correlates
with the increase in trafficking and lysosomal activity of L444P GC
[14]. Interestingly, despite causing moderate activation of the
UPR, lacidipine treatment was observed to prevent apoptosis
induction, effectively promoting cell survival [14].
We hypothesized that restoring Ca2+ homeostasis in GD cells
creates a folding environment that could be particularly amenable
to enhance native folding and trafficking of mutated GC mediated
by ERAD inhibition. Thus, we attempted remodeling the
proteostasis network by simultaneously i) inhibiting ERAD
degradation to increase ER retention of unstable intermediates
and ii) restoring Ca2+ homeostasis to enhance chaperone-mediated
folding (Figure 1A). We report herein that this strategy results in
dramatic increase in the folding, trafficking and activity of the
most severely destabilized GC variant, L444P GC. Moreover, we
demonstrated that modulation of Ca2+ homeostasis via lacidipine
treatment lowers UPR induction and apoptosis caused by ERAD
inhibition. Results from this study provide novel insights for the
development of effective therapeutic strategies for the treatment of
GD based on remodeling the proteostasis network to rescue the
folding of unstable, degradation-prone GC variants.
Materials and Methods
Enzyme Activity Assays
The intact cell glucocerebrosidase (GC) activity assay was
performed as described previously [10] and in File S1.
Quantitative RT-PCR
Quantitative RT-PCR was performed as described previously
[15] and in Materials S1 using the primers listed in Table S1.
Western Blot Analyses and Immunofluorescence
Microscopy
Details are provided in File S1.
siRNA Transfection
Transfection procedures were performed as described in
manufacturer’s manual: briefly, 12.5 ng siRNA was diluted in
3 ml of RNase-free water and was spotted into each well of a 96-
well plate. 0.75 ml of HiPerFect reagent was resuspended in 25 ml
of culture medium without serum and was added to the prespotted
siRNA. After incubating for 10 min at room temperature to allow
complex formation, 104 cells in 150 ml of growth medium were
plated directly into each well. Small molecules were added to the
medium 48 hrs post transfection at concentrations indicated in the
text. Quantitative RT-PCR was performed after 24 hrs and
lysosomal GC activity was measured after 48 hrs.
Toxicity Assay
Toxicity assays were conducted as described previously [15] and
in File S1.
Statistical Analysis
All data is presented as mean 6 s.d., and statistical significance
was calculated using one-way ANOVA analysis followed by post-
hoc Tukey’s test.
Results
Modulation of Ca2+ Homeostasis Enhances the Rescue of
L444P GC Folding, Trafficking and Activity Induced by
ERAD Inhibition in GD Fibroblasts
We previously reported that the folding of mutated GC variants
is partially rescued by inhibiting specific steps of the ERAD
pathway in GD cells [15]. In the present study, we asked whether
enhancing the cellular folding capacity via modulation of
intracellular Ca2+ homeostasis could increase the fraction of
natively folded GC mutants rescued by inhibiting ERAD
(Figure 1A) [13,14]. We co-administered the LTCC blocker
lacidipine, which lowers cytosolic [Ca2+] in GD fibroblasts [14],
and Eeyarestatin I (EerI), which blocks the ERAD pathway by
inhibiting the p97 ATPase [16,17], to fibroblasts derived from GD
patients homozygous for the L444P GC allele and investigated the
activity and intracellular trafficking of mutated GC. Experiments
were performed by administrating a constant concentration of
lacidipine (5, 10, or 20 mM) to GD fibroblasts that were cultured in
medium supplemented with a range of EerI concentrations. GC
enzymatic activity was evaluated every 24 hrs for up to 72 hrs with
the intact cell GC activity assay (Figures 1B and S1). Culturing
conditions resulting in maximal rescue of L444P GC activity are
reported in Figure 1B. Co-treatment with EerI (6 mM) and
lacidipine (20 mM) for 48 hrs resulted in 2.9-fold increase in
L444P GC activity compared to untreated cells (ANOVA,
p,0.001; F= 16; Figure 1B), which corresponds to 36.3% of
WT activity and is compatible with effective treatment [2]. This
increase in GC activity is significantly higher (p,0.001) than that
measured in cells treated only with EerI (1.6-fold; ANOVA,
p,0.01, F= 22) or lacidipine (1.8-fold; ANOVA, p,0.01, F = 16)
under the same conditions and was still observed after 72 hrs of
incubation (EerI 6 mM and lacidipine 20 mM, 2.6-fold increase in
GC activity; ANOVA, p,0.01, F = 14; Figure S1).
In order to verify that the increase in GC activity observed in
cells treated with EerI and lacidipine is due to rescue of L444P GC
folding and lysosomal trafficking, we investigated L444P GC
intracellular localization. Cells were treated to obtain maximal
increase in GC activity and analyzed by immunofluorescence
microscopy. Specifically, L444P GC fibroblasts were cultured with
EerI (6 mM), lacidipine (10 mM) and a combination thereof for
48 hrs. Localization of GC in the ER and in the lysosomes was
detected with antibodies specific for GC, for an ER marker
(CNX), and for a lysosomal marker (LAMP-1). Co-localization of
GC and CNX (Figure 1C) and of GC and LAMP-1 (Figure 1D)
are shown in pink and purple, respectively, in merged images. As
shown in heatmaps of co-localization images, L444P GC was
barely detectable in untreated cells due to extensive ERAD, as
expected [10]. Treatment with lacidipine or EerI enhanced the
pool of GC that accumulates both in the ER and in the lysosomes,
as previously reported [14,15]. The addition of lacidipine to EerI
treatment resulted in accumulation of GC in the ER similar to that
observed in cells treated only with EerI. However, co-treatment
with lacidipine and EerI resulted in an increase in accumulation of
GC in the lysosomes compared to cells treated with either EerI or
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Figure 1. Co-treatment with EerI and lacidipine enhances lysosomal trafficking and activity of L444P GC. (A) Lacidipine and EerI
modulate distinct pathways of the proteostasis network that regulate the processing of GC. Lacidipine enhances ER folding by restoring Ca2+
homeostasis in GD cells [14]. Specifically, lacidipine inhibits extracellular Ca2+ influx through L-type voltage-gated Ca2+ channels (LTCC) on the plasma
membrane and blocks ER Ca2+ efflux through ryanodine receptors (RyRs) on the ER membrane, thus restoring the intracellular gradient of [Ca2+]. EerI
treatment enhances retention of unstable proteins in the ER. Particularly, EerI inhibits p97 ATPase activity, which promotes retro-translocation of
misfolded substrates from the ER to the cytoplasm for ER-associated degradation (ERAD). (B) L444P GC activities of GD cells treated with a range of
concentrations of EerI and constant doses of lacidipine (5, 10, or 20 mM) for 48 hrs. Relative GC activities were evaluated by normalizing GC activities
measured in treated cells to the activity in untreated cells (left y axis), (ANOVA, p,0.01 if not specified; *p,0.001). The corresponding fraction of WT
GC activity is also reported (right y axis). Experiments were repeated three times and data points are reported as mean 6 SD. Lac, lacidipine. (C–D)
Immunofluorescence microscopy of GC and CNX (an ER marker), and GC and LAMP-1 (a lysosomal marker) in L444P GC fibroblasts. Cells were treated
with EerI (6 mM), and lacidipine (10 mM) for 48 hrs. (C) Colocalization of CNX (grey, column 1) and GC (red, column 2) is shown in pink (column 3). (D)
Colocalization of LAMP-1 (blue, column 1) and GC (red, column 2) is shown in purple (column 3). Heatmaps of co-localization images were obtained
with NIH ImageJ analysis software (column 4). Hot colors represent positive correlation (co-localization), whereas cold colors represent negative
correlation (exclusion).
doi:10.1371/journal.pone.0061418.g001
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lacidipine (Figure 1CD). These results are compatible with a model
in which combining modulation of Ca2+ homeostasis and ERAD
inhibition enhances rescue of GC folding intermediates that escape
ERAD and promotes their trafficking through the secretory
pathway, thereby leading to the increase in lysosomal GC activity
observed from enzymatic assays (Figure 1B).
Lacidipine Lowers Cytosolic Free [Ca2+] in GD Fibroblasts
Treated with EerI
The accumulation of glucosylceramide in GD cells causes Ca2+
efflux from the ER and increases free cytosolic [Ca2+] [18]. We
previously showed that lacidipine treatment lowers cytosolic
[Ca2+] in GD fibroblasts and, in turn, is associated with an
increase in mutated GC folding and activity. Since administration
of lacidipine to EerI-treated cells increases the residual activity of
L444P GC (Figure 1B), we asked whether this difference in activity
could be attributed to the mobilization of intracellular Ca2+. We
evaluated cytosolic free [Ca2+] in L444P GC fibroblasts treated
with EerI (6 mM), lacidipine (10 mM) and a combination thereof
by measuring fluctuations in the Fura-2 fluorescence ratio
(340 nm/380 nm) [23]. EerI treatment alone did not seem to
alter intracellular [Ca2+] in GD fibroblasts. However, the addition
of lacidipine to EerI-treated cells lowered free cytosolic [Ca2+]
(Figure 2). Interestingly, the free cytosolic [Ca2+] in GD cells
treated with lacidipine was lower than that observed in cells co-
treated with lacidipine and EerI, suggesting that either minimal
intracellular Ca2+ mobilization is sufficient to enhance L444P GC
folding and activity or that the increase in L444P GC activity
obtained upon co-administration of lacidipine and EerI is due to
additional or alternative effects of these compounds on the
proteostasis network.
Lacidipine Attenuates the Cytotoxic Effect of EerI-
mediated ERAD Inhibition in GD Fibroblasts
EerI treatment causes accumulation of misfolded intermediates
in the ER and, consequently, ER stress and induction of the UPR
[15]. Moderate UPR induction was repeatedly reported to
promote the rescue of misfolding-prone GC variants [10,13–15].
However, prolonged UPR induction observed upon sustained
treatment with EerI causes activation of apoptosis [14,15]. Cell
treatment with lacidipine, on the other hand, was shown not to
cause cytotoxicity under conditions observed to rescue the folding
of mutated GC variants [14].
We asked whether lacidipine treatment could counteract the
cytotoxic effect of EerI and evaluated apoptosis in cells co-treated
with lacidipine and EerI. Specifically, we monitored membrane
rearrangement (Annexin V binding) and fragmentation (propi-
dium iodide (PI) binding) that occur during early and late
apoptosis, respectively, using the CytoGLOTM Annexin V-FITC
Apoptosis Detection Kit. L444P GC fibroblasts were cultured with
lacidipine (10 mM) and EerI (6 mM) for 16 hrs (Figure 3A–B).
Similar to what previously reported [14,15], Annexin V binding
affinity in cells treated with lacidipine was comparable to that
measured in untreated cells, whereas a dramatic increase in
Annexin V binding was observed in cells treated with EerI,
reflecting the onset of apoptosis. The addition of lacidipine to
EerI-treated cells resulted in significant decrease in Annexin V
binding compared to cells treated only with EerI (14% decrease;
ANOVA, p,0.01), suggesting that lacidipine treatment partially
alleviates the cytotoxic effect of EerI (Figure 3A). Cell death was
measured by monitoring the change in PI binding population. A
negligible increase (0.3%) in PI binding was observed upon
lacidipine treatment, while EerI treatment caused 10.4% increase
in PI binding (ANOVA, p,0.01; Figure 3B). The addition of
lacidipine to EerI-treated cells reduced the PI binding population
to 6.7% (ANOVA, p,0.01), confirming that lacidipine treatment
has an anti-apoptotic effect.
These results, taken together, demonstrate that lacidipine
treatment enhances EerI-mediated rescue of mutated GC native
folding and activity and that it also counteracts EerI cytotoxic
effect. Moreover, lacidipine treatment protects the cells from
apoptosis associated with prolonged UPR induction, a particularly
appealing property for development of therapeutic strategies based
on the modulation of the proteostasis network.
Lacidipine Remodels EerI-mediated Activation of the UPR
Pathway
EerI, when administered under conditions that result in
maximal increase in L444P GC activity, is associated with
significant UPR induction and cell apoptosis, whereas lacidipine
treatment induces UPR but does not cause apoptosis [14,15]. We
reported above that co-administration of lacidipine and EerI
lowers apoptosis compared to treatment with EerI only (Figure 3).
Therefore, we asked whether co-treatment of GD cells with EerI
and lacidipine activates the UPR. The UPR is a complex tripartite
pathway regulated by three transmembrane signal transducers,
namely inositol requiring kinase 1 (IRE1), activating transcription
factor 6 (ATF6) and double-stranded RNA-activated ER kinase
(PERK). Activation of these three sensors leads to transcriptional
regulation of a series of UPR target genes that mediate cellular
folding [26,27]. In order to evaluate UPR induction, we measured
the expression of three representative UPR target proteins: X-box
binding protein-1 (Xbp-1), which is activated by IRE1; activating
transcription factor 4 (ATF4), which is part of the PERK signaling
cascade; and C/EBP homologous protein (CHOP), which is
upregulated in response to ATF6 activation [27]. Quantitative
RT-PCR was conducted to evaluate the transcription levels of
Xbp-1, ATF4, and CHOP in cells treated with lacidipine (10 mM)
and EerI (6 mM).
Xbp-1 mRNA is spliced upon activation of the IRE1 signaling
cascade. The protein encoded by the spliced Xbp-1 mRNA
functions as an activator of the IRE1 branch of the UPR, while
the protein encoded by the unspliced precursor acts as a repressor
[26]. Spliced and unspliced forms of Xbp-1 mRNA were analyzed
by RT-PCR followed by gel electrophoresis. Bands corresponding
Figure 2. Lacidipine reduces cytosolic [Ca2+] in GD fibroblasts
treated with EerI. GD fibroblasts were cultured with lacidipine
(10 mM) and EerI (6 mM) for 5, 10, 20 and 40 min, respectively. Cytosolic
[Ca2+] level was evaluated by measuring excitation 340/380 ratio of
fura-2 acetoxymethyl ester and normalized to that at time zero. Each
data point was repeated three times and reported as mean 6 SD.
doi:10.1371/journal.pone.0061418.g002
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to spliced Xbp-1 mRNA were quantified with NIH ImageJ
software to evaluate the activation level of the IRE1 arm of the
UPR (Figure 4A–B). Xbp-1 splicing in cells treated with lacidipine
or with EerI was previously investigated [14,15]. Thus, EerI- and
lacidipine-treated cells are reported here as control samples. In
agreement with what reported before [14], the amount of spliced
Xbp-1 in lacidipine treated cells was similar to that measured in
untreated cells, while a considerable amount of spliced Xbp-1 was
observed in cells treated with EerI [15]. In cells treated with both
lacidipine and EerI, the amount of spliced Xbp-1 was found to
increase 1.8-fold compared to cells treated only with EerI,
suggesting an additive effect of lacidipine and EerI on the
induction of the IRE1 arm. Interestingly, Xbp-1 is an essential
pro-survival UPR component and its activation is associated with
attenuated apoptosis under ER stress conditions [28]. Thus,
enhanced splicing of Xbp-1 in cells treated with lacidipine and EerI
correlates with the decrease in apoptosis induction observed in
cells treated under same conditions.
The expression level of ATF4 was evaluated in order to monitor
the activation of the PERK branch. ATF4 transcriptional
expression was upregulated 1.8- and 4.4-fold in cells treated with
lacidipine and EerI, respectively, compared to untreated cells. Co-
treatment with lacidipine and EerI reduced ATF4 expression to
only 2.1-fold of that of untreated cells (ANOVA, p,0.05),
suggesting that lacidipine suppresses EerI-mediated activation of
the PERK arm (Figure 4C). Since the PERK arm of the UPR
regulates the pro-apoptotic pathway activated in response to
sustained UPR induction [29], these results support the notion that
lacidipine lowers the apoptotic effect of EerI.
CHOP, a downstream effector of the ATF6 branch, is
upregulated by both lacidipine and EerI treatment (6.1- and
18.5-fold, respectively; Figure 4D). The addition of lacidipine to
EerI-treated cells lowered CHOP upregulation to 14.7-fold
(ANOVA, p,0.05). CHOP mediates UPR induced apoptosis
activation [30]. Hence, these results again suggest a correlation
between lacidipine’s anti-apoptotic effect and its ability to remodel
the UPR pathway activated by EerI.
Lacidipine treatment alters the expression of genes involved in
the regulation of UPR-induced apoptosis, and, particularly, it
upregulates the anti-apoptotic gene Bcl-2. We therefore asked
whether the protective effect of lacidipine treatment observed in
EerI-treated cells could be attributed to the upregulation of Bcl-2
[14]. The expression level of Bcl-2 was evaluated by quantitative
RT-PCR in cells cultured with lacidipine (10 mM) and EerI
(6 mM). Lacidipine treatment resulted in 3.0-fold increase in Bcl-2
expression compared to untreated cells, while EerI treatment
caused a 2.0-fold decrease. Bcl-2 expression was also significantly
upregulated (4.2-fold; ANOVA, p,0.05) in cells co-treated with
lacidipine and EerI (Figure 4E).
The gene encoding GC (GBA), as well as other genes encoding
for lysosomal proteins that are associated with the development of
LSD, is upregulated in cells treated with proteostasis modulators
[14,15]. We thus asked whether the dramatic increase in L444P
GC activity observed upon modulation of intracellular Ca2+
homeostasis and inhibition of ERAD could be attributed to
Figure 3. Lacidipine attenuates induction of apoptosis in GD cells treated with EerI. (A) Flow cytometry histograms of Annexin V-FITC
fluorescence intensities (x-axis, log scale) plotted against cell counts (y-axis, linear scale) obtained from the analysis of untreated cells and cells treated
with lacidipine (10 mM) and EerI (6 mM). Three independent experiments were conducted and results of one representative experiment are reported.
(B) PI binding population change (%) of cells treated with lacidipine (10 mM) and EerI (6 mM) for 16 hrs compared to untreated cells (ANOVA, p,0.01).
Number of total cells counted: 10,000. The data is reported as mean 6 SD.
doi:10.1371/journal.pone.0061418.g003
Remodeling Proteostasis in Gaucher Disease Cells
PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e61418
upregulation of GC transcription in addition to rescue of GC
folding and inhibition of GC degradation. The expression of GBA
in GD fibroblasts treated with lacidipine (10 mM) and EerI (6 mM)
was measured by quantitative RT-PCR. Co-administration of
lacidipine and EerI resulted in 5.2-fold upregulation of GC
expression compared to untreated cells (ANOVA, p,0.05), which
Figure 4. Lacidipine remodels the UPR pathway in GD fibroblasts treated with EerI. Cells were treated with lacidipine (10 mM) and EerI
(6 mM) for 24 hrs. (A) Xbp-1 mRNA splicing was determined by RT-PCR followed by gel electrophoresis. (B) Spliced Xbp-1 band intensities were
quantified with NIH ImageJ analysis software. Relative mRNA expression levels of (C) ATF4, (D) CHOP, (E) Bcl-2, and (F) GC were obtained by
quantitative RT-PCR, corrected by the expression of the housekeeping gene GAPDH, and normalized by that of untreated cells (ANOVA, p,0.05). The
data is reported as mean6 SD. (G) Western blot analysis of cells treated with EerI (6 mM) and lacidipine (10 mM) for 48 hrs using GC specific antibody.
GAPDH expression was used as a loading control. (H) Western blot band quantification. GC bands were quantified by NIH ImageJ analysis software
and corrected by GAPDH band intensities.
doi:10.1371/journal.pone.0061418.g004
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is higher than what observed in cells treated only with lacidipine
(2.5-fold) or EerI (3.3-fold) (Figure 4F).
GC expression was also evaluated by Western blot (Figure 4G–
H). As shown in Figure 4H, L444P GC content was barely
detectable in untreated cells, as expected, due to extensive ERAD
[8], but it was enhanced by treatment with either lacidipine or
EerI. In agreement with the results obtained from quantitative
RT-PCR analyses, co-treatment with lacidipine and EerI further
enhanced GC accumulation (1.4-fold increase compared to EerI
treatment alone).
Among ER resident chaperones, BiP plays a critical role in the
folding of mutated GC variants [13,14]. The increase in lysosomal
GC activity observed upon chemically induced inhibition of
ERAD or modulation of intracellular Ca2+ homeostasis in GD
cells is partially due to the upregulation of BiP expression
associated with UPR induction. Thus, we evaluated BiP expres-
sion in cells treated with lacidipine and EerI and compared it to
that of other ER chaperones Calnexin (CNX) and Calreticulin
(CRT). The total protein content of treated and untreated cells
was analyzed by Western blot using a BiP-specific antibody
(Figure 5A–B). Co-administration of lacidipine and EerI resulted
in 3.6-fold increase in BiP cellular accumulation, which is lower
than what observed in cells treated only with EerI (4.3-fold). CNX
and CRT protein levels were not significantly altered by co-
treatment with lacidipine and EerI. BiP is normally upregulated
upon activation of the UPR [27]. Thus, the decrease in BiP
expression observed in cells treated with EerI and lacidipine
correlates with lacidipine-mediated attenuation of UPR induction.
Bcl-2 does not Directly Affect Mutated GC Folding but
Protects GD Cells from Apoptosis Associated with
Modulation of Proteostasis
Bcl-2 is the prototype of an expanding family of proteins that
regulate cell survival and apoptosis in multiple cell types [31]. As
discussed above, treatment with lacidipine prevents apoptosis
associated with UPR induction that was observed upon treatment
with EerI. The addition of lacidipine to EerI treated cells results in
upregulation of Bcl-2 expression to a considerably higher level
than what is observed administering EerI alone (Figure 4E). In
order to investigate the role of Bcl-2 in cells treated for the rescue
of mutated GC folding via UPR induction, we treated GD cells
with fluvastatin, a compound that was previously reported to
induce upregulation of Bcl-2 [32]. Specifically, we asked whether
fluvastatin treatment could counteract the apoptotic effect of
prolonged UPR induction. Fluvastatin was administered to GD
cells treated with UPR inducing proteostasis modulators known to
rescue native folding of mutated GC, namely EerI and MG-132.
MG-132 inhibits proteasomal degradation, which, in turn, causes
induction of UPR and upregulation of chaperones in GD cells
[10]. Co-treatment with EerI and MG-132 was found to
dramatically enhance the activity of L444P GC (to 52% of WT
activity), but at the cost of even higher induction of apoptosis [15].
We administered fluvastatin (100 nM) to GD cells treated with
EerI (2 and 6 mM) and MG-132 (0.6 mM) and tested Bcl-2
expression, induction of apoptosis and GC activity. Fluvastatin
treatment caused dramatic upregulation of Bcl-2 (18.4-fold
compared to untreated cells; p,0.05) and did not induce
cytotoxicity (Figure 6A–B). The addition of fluvastatin to EerI-
treated cells also upregulated Bcl-2 and lowered apoptosis.
Specifically, fluvastatin treatment increased Bcl-2 expression in
cells treated with EerI 2 mM (4.6-fold) and with EerI 6 mM (5.2-
fold) (p,0.05; Figure 6A). Fluvastatin treatment also reduced
apoptosis caused by EerI, reducing cell death by 40% in cells
treated with EerI 6 mM (p,0.01; Figure 6B). Similar results were
obtained upon addition of MG-132. Bcl-2 expression was
downregulated in cells treated with both EerI and MG-132 (0.8-
fold) compared to untreated cells. However, the addition of
fluvastatin caused upregulation of Bcl-2 expression (2.8-fold;
ANOVA, p,0.05) compared to untreated cells. The addition of
fluvastatin also resulted in a decrease in cell death (40%; ANOVA,
p,0.01) compared to cells treated only with EerI and MG-132.
These results suggest that Bcl-2 plays a protective role in GD cells
treated with proteostasis modulators that induce the UPR and
activate apoptosis.
To test whether chemically induced upregulation of Bcl-2
expression affects rescue of L444P GC activity, we also measured
GC activity in GD cells cultured under the same conditions
(Figures 6C and S2). Interestingly, chemically induced upregula-
tion of Bcl-2 expression did not alter the increase in L444P GC
activity mediated by UPR induction.
To further investigate the role of Bcl-2 in GD cells cultured with
proteostasis modulators, we asked whether the genetic modulation
of Bcl-2 expression correlates with apoptosis induction in cells
treated with EerI and lacidipine. To this end, we downregulated
the expression of Bcl-2 using small interfering RNA (siRNA) and
evaluated apoptosis induction and GC activity. L444P GC
fibroblasts were incubated with siRNA against endogenous Bcl-2
for 48 hrs followed by small molecule treatment (lacidipine 10 mM
and EerI 6 mM) for additional 48 hrs (Figure 7). Non-targeting
siRNA was used as a siRNA knockdown control. To determine the
extent of silencing achieved, we first measured Bcl-2 expression by
Figure 5. Lacidipine attenuates BiP upregulation in GD cells treated with EerI. (A) Western blot analyses of BiP, CNX, CRT, and GAPDH (used
as loading control) in GD fibroblasts treated with lacidipine (10 mM) and EerI (6 mM) for 48 hrs. (B) Quantification of Western blot bands. ER
chaperone band intensities were quantified with NIH ImageJ analysis software, corrected by GAPDH band intensities, and divided by the values
obtained from untreated samples.
doi:10.1371/journal.pone.0061418.g005
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quantitative RT-PCR (Figure 7A). Bcl-2 siRNA resulted in 50%
downregulation of Bcl-2 expression compared to non-targeting
siRNA in untreated cells. Bcl-2 silencing was also observed to
reduce Bcl-2 expression in cells treated with lacidipine or EerI,
confirming that the knockdown of endogenous Bcl-2 was achieved
in both untreated and small molecule-treated cells.
Administration of Bcl-2 siRNA to achieve partial (50%)
downregulation of its expression did not significantly change the
induction of apoptosis (monitored by measuring PI binding as
described above, Figure 3) in either untreated or lacidipine treated
cells (Figure 7B). However, reducing the expression of Bcl-2 in
EerI-treated cells resulted in significantly higher apoptosis in-
duction leading to a 35% increase in cell death (Figure 7B). These
data suggest that Bcl-2 plays a key role in preventing induction of
apoptosis associated with sustained UPR activation.
To investigate whether silencing Bcl-2 expression influences the
increase in L444P GC residual activity achieved with proteostasis
modulators, we also tested GC activity in GD cells treated under
the same conditions (Figure 7C). Not surprisingly, Bcl-2 siRNA did
not significantly alter GC activity in cells treated with lacidipine
and EerI, confirming that modulating the expression of Bcl-2 does
not influence folding of mutated GC.
Discussion
LSDs comprise a class of more than 50 inherited diseases. They
are individually rare, but collectively represent one of the most
prevalent genetic disorders in children [33,34]. GD is the most
common LSD (1 in 60,000 people) with the highest frequency in
the Ashkenazi Jewish population (1 in 1,000) [35]. It presents
highly variable clinical manifestations ranging from adult forms to
acute or chronic infantile neuronopathic types [6]. Enzyme
replacement therapy is currently available for most patients, but
fails to treat several affected areas, particularly the skeleton and the
brain [36]. Bone marrow transplantation can reverse non-
neurological aspects of the disease, but it is rarely performed
[37]. Inhibitors of glucosylceramide synthesis are available for the
treatment of GD patients with moderate clinical manifestations for
which enzyme replacement therapy cannot be considered an
option [38]. In summary, there is no effective treatment for
neurological symptoms that affect the brain damage that occurs in
the most severe cases of GD.
The most prevalent mutations in gene encoding GC (GBA,
NM_000157) result in single amino acid substitutions that do not
directly impair enzymatic activity but destabilize the protein
structure, leading to its degradation via ERAD [5]. These
misfolding-prone GC variants, however, retain catalytic activity
if forced to fold into their native structure [7–10]. In an effort to
design therapeutic strategies that overcome the blood brain barrier
and ameliorate symptoms in the central nervous systems,
increasing focus has been recently devoted to the development
of small molecule based strategies to rescue native folding of GC
variants containing non-inactivating, destabilizing mutations and
enhance their lysosomal targeting and activity. Particularly,
modulating the proteostasis network to upregulate the synthesis,
Figure 6. Upregulation of Bcl-2 protects GD cells from
apoptosis induced by proteostasis modulators. (A) Relative
mRNA expression levels of Bcl-2 in cells treated with EerI (2 and 6 mM),
MG-132 (0.6 mM), and fluvastatin (100 nM) for 24 hrs evaluated by
quantitative RT-PCR and calculated as described in Figure 4 (ANOVA,
p,0.05). (B) PI binding population change (%) of cells treated with EerI
(2 and 6 mM), MG-132 (0.6 mM), and fluvastatin (100 nM) for 16 hrs
compared to untreated cells (p,0.01). The data is reported as mean 6
SD. Number of total counted cells: 10,000. (C) L444P GC activities of GD
fibroblasts treated with EerI (2 and 6 mM), MG-132 (0.6 mM), and
fluvastatin (100 nM) for 48 hrs. Relative GC activities were evaluated as
described in Figure 1B (ANOVA, p,0.01). Experiments were repeated
three times and data points are reported as mean 6 SD. MG, MG-132;
Flu, fluvastatin.
doi:10.1371/journal.pone.0061418.g006
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folding and processing of secretory proteins holds significant
promise to efficiently rescue protein homoeostasis in GD cells [10].
A variety of small molecules including proteasome inhibitors
[10,39], Ca2+ blockers [13,14], and ERAD inhibitors [15] were
reported to enhance folding and activity of the most destabilized
GC variant containing the L444P substitution, which is the most
prevalent mutation in GD patients with CNS symptoms.
However, the mechanism of action of these proteostasis mod-
ulators involves induction of ER stress and activation of the UPR.
Sustained activation of the UPR, in turn, can lead to apoptosis
thus ultimately compromising effective rescue of protein homeo-
stasis. In this study, we sought to investigate chemical strategies to
selectively modulate different branches of the proteostasis network
that enhance rescue of L444P GC folding, while preventing
proteotoxic stress and apoptosis.
We previously reported that inhibition of specific steps of ERAD
leads to rescue of L444P GC folding and activity. As expected,
ERAD inhibition enhances retention of unstable GC in the ER
and ultimately results in enhanced lysosomal trafficking and
activity, but it also leads to significant UPR induction and
apoptosis [15]. On the other hand, restoring Ca2+ homeostasis via
lacidipine treatment proved to be an effective strategy to modulate
the cellular folding capacity and rescue L444P GC folding and
activity without, however, inducing apoptosis [14]. In this study,
we attempted to simultaneously increase retention of GC folding
intermediates into the ER (via ERAD inhibition) and enhance ER
folding (by restoring Ca2+ homeostasis). We found that combining
these two mechanisms of proteostasis modulation enhances
lysosomal trafficking and activity of L444P GC (Figure 1). Most
importantly, we proved that the observed increase in GC activity
was accompanied by lowered apoptosis induction, which suggests
that lacidipine treatment protects GD cells from induction of
UPR-associated apoptotic response.
Lacidipine treatment remodels the UPR pathway activated by
EerI. Remodeling of the UPR, in turn, seems to be tightly linked
to lacidipine’s anti-apoptotic function. Signal transducers of the
UPR can activate either cytoprotective or pro-apoptotic pathways
[29]. A pro-survival response is first initiated to reduce the load of
misfolded proteins by boosting the ERAD pathway [40]. This
response is mediated by the induction of the IRE1 signaling
cascade [41] via Xbp-1 splicing and activation [28]. If the
proteotoxic stress persists, pro-apoptotic signals are elicited
through the activation of the PERK and ATF6 signaling cascades
through the expression of ATF4 and its target CHOP. Induction
of this pro-apoptotic response occurs simultaneously to attenuate
IRE1 signaling [29,42]. We found that lacidipine enhances EerI-
mediated Xbp-1 splicing and lowers the activation of ATF4 and
CHOP. These results suggest that lacidipine remodels EerI-
mediated UPR induction by activating the anti-apoptotic IRE1
signaling cascade and inhibiting the activation of the pro-apoptotic
PERK and ATF6 arms.
The Bcl-2 protein family plays a key role in the activation of
UPR-associated apoptosis [43]. Particularly, Bcl-2 is an essential
anti-apoptotic protein that controls cell survival [31] and is
possibly involved in maintaining Ca2+ homeostasis by reducing
[Ca2+]ER efflux [44,45]. Bcl-2 is upregulated upon treatment of
GD fibroblasts with lacidipine [14]. We showed herein that
lacidipine enhances the expression of Bcl-2 in EerI-treated cells
Figure 7. Silencing Bcl-2 aggravates the apoptotic effect of
proteostasis modulators. (A) Relative mRNA expression levels of Bcl-
2 in GD fibroblasts incubated with siRNA for 48 hrs and treated with
lacidipine (10 mM) and EerI (6 mM) for additional 24 hrs evaluated by
quantitative RT-PCR and calculated as described in Figure 4 (ANOVA,
p,0.05). (B) Flow cytometry analysis of PI binding population change
(%) of GD fibroblasts incubated with siRNA for 48 hrs followed by
lacidipine (10 mM) and EerI (6 mM) treatment for 16 hrs (ANOVA,
p,0.01). The change in PI binding population (%) was calculated by
subtracting PI binding values of cells treated with small molecules to
that of cells only incubated with control siRNA. The data is reported as
mean 6 SD. Number of total counted cells: 10,000. (C) Relative L444P
GC activities in cells incubated with Bcl-2 or control siRNA for 48 hrs
followed by lacidipine (10 mM) and EerI (6 mM) treatment for additional
48 hrs. Relative GC activities were evaluated as described in Figure 1B
(ANOVA, p,0.01). Experiments were repeated three times and data
points are reported as mean 6 SD. Lac, lacidipine.
doi:10.1371/journal.pone.0061418.g007
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and protects cells from EerI-mediated apoptosis induction. We
also reported direct evidence that the expression level of Bcl-2
plays a protective role in GD cells treated with proteostasis
modulators that activate the pro-apoptotic arms of the UPR.
In conclusion, this study demonstrates that combining modu-
lation of Ca2+ homeostasis and ERAD inhibition enhances the ER
folding capacity of GD fibroblasts thereby enabling efficient rescue
of folding, trafficking and activity of L444P GC. Generally
speaking, there is a clear correlation between protein stability and
extent of degradation and residual enzymatic activity of GC
variants containing destabilizing, non-inactivating mutations.
Accordingly, modulation of the proteostasis network typically
result in higher rescue of enzymatic activity in cells expressing
highly destabilized GC variants, such as L444P GC, than in cells
expressing less unstable variants that retain higher enzymatic
activity, such as N370S GC [15]. The results reported herein
provide insights for the development of pharmacologic strategies
to modulate the proteostasis network and rescue native folding of
unstable, degradation-prone proteins traversing the secretory
pathway without triggering induction of ER stress and activation
of apoptosis.
Supporting Information
Figure S1 Co-treatment of GD patient-derived fibro-
blasts with EerI and lacidipine enhances the folding,
lysosomal trafficking and activity of L444P GC. Relative
L444P GC activities were evaluated in cells treated with a range of
concentrations of EerI and constant doses of lacidipine (5, 10, or
20 mM) for 72 hrs. Relative GC activities were evaluated by
normalizing GC activities measured in treated cells to the activity
in untreated cells (left y axis). The corresponding fraction of WT
GC activity is also reported (right y axis). Experiments were
repeated three times and data points are reported as mean 6 SD.
Lac, lacidipine.
(DOCX)
Figure S2 Chemically induced upregulation of Bcl-2
enhances mutated GC activity rescue. Relative L444P GC
activities of GD fibroblasts treated with EerI (2 and 6 mM), MG-
132 (0.6 mM), and fluvastatin (100 nM) for 72 hrs. Relative GC
activities were evaluated as described in Figure S1. Experiments
were repeated three times and data points are reported as mean 6







Conceived and designed the experiments: FW LS. Performed the
experiments: FW. Analyzed the data: FW. Contributed reagents/
materials/analysis tools: FW. Wrote the paper: FW LS.
References
1. Futerman AH, van Meer G (2004) The cell biology of lysosomal storage
disorders. Nat Rev Mol Cell Biol 5: 554–565.
2. Schueler UH, Kolter T, Kaneski CR, Zirzow GC, Sandhoff K, et al. (2004)
Correlation between enzyme activity and substrate storage in a cell culture
model system for Gaucher disease. J Inherit Metab Dis 27: 649–658.
3. Hruska KS, LaMarca ME, Scott CR, Sidransky E (2008) Gaucher disease:
mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).
Hum Mutat 29: 567–583.
4. Schmitz M, Alfalah M, Aerts JM, Naim HY, Zimmer KP (2005) Impaired
trafficking of mutants of lysosomal glucocerebrosidase in Gaucher’s disease.
Int J Biochem Cell Biol 37: 2310–2320.
5. Grace ME, Newman KM, Scheinker V, Berg-Fussman A, Grabowski GA (1994)
Analysis of human acid beta-glucosidase by site-directed mutagenesis and
heterologous expression. J Biol Chem 269: 2283–2291.
6. Grabowski GA (1997) Gaucher disease: gene frequencies and genotype/
phenotype correlations. Genet Test 1: 5–12.
7. Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, et al. (2002)
Chemical chaperones increase the cellular activity of N370S beta -glucosidase:
a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A 99: 15428–
15433.
8. Sawkar AR, Schmitz M, Zimmer KP, Reczek D, Edmunds T, et al. (2006)
Chemical chaperones and permissive temperatures alter localization of Gaucher
disease associated glucocerebrosidase variants. ACS Chem Biol 1: 235–251.
9. Yu Z, Sawkar AR, Whalen LJ, Wong CH, Kelly JW (2007) Isofagomine- and
2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological
chaperones for Gaucher disease intervention. J Med Chem 50: 94–100.
10. Mu TW, Ong DS, Wang YJ, Balch WE, Yates JR 3rd, et al. (2008) Chemical
and biological approaches synergize to ameliorate protein-folding diseases. Cell
134: 769–781.
11. Sawkar AR, Adamski-Werner SL, Cheng WC, Wong CH, Beutler E, et al.
(2005) Gaucher disease-associated glucocerebrosidases show mutation-depen-
dent chemical chaperoning profiles. Chem Biol 12: 1235–1244.
12. Khanna R, Benjamin ER, Pellegrino L, Schilling A, Rigat BA, et al. (2010) The
pharmacological chaperone isofagomine increases the activity of the Gaucher
disease L444P mutant form of beta-glucosidase. FEBS J 277: 1618–1638.
13. Wang F, Agnello G, Sotolongo N, Segatori L (2011) Ca2+ homeostasis
modulation enhances the amenability of L444P glucosylcerebrosidase to
proteostasis regulation in patient-derived fibroblasts. ACS Chem Biol 6: 158–
168.
14. Wang F, Chou A, Segatori L (2011) Lacidipine remodels protein folding and
Ca2+ homeostasis in Gaucher’s disease fibroblasts: a mechanism to rescue
mutant glucocerebrosidase. Chem Biol 18: 766–776.
15. Wang F, Song W, Brancati G, Segatori L (2011) Inhibition of endoplasmic
reticulum-associated degradation rescues native folding in loss of function
protein misfolding diseases. J Biol chem 286: 43454–43464.
16. Fiebiger E, Hirsch C, Vyas JM, Gordon E, Ploegh HL, et al. (2004) Dissection of
the dislocation pathway for type I membrane proteins with a new small molecule
inhibitor, eeyarestatin. Mol Biol Cell 15: 1635–1646.
17. Wang Q, Shinkre BA, Lee JG, Weniger MA, Liu Y, et al. (2010) The ERAD
inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding
domain and a p97/VCP inhibitory group. PLoS One 5: e15479.
18. Korkotian E, Schwarz A, Pelled D, Schwarzmann G, Segal M, et al. (1999)
Elevation of intracellular glucosylceramide levels results in an increase in
endoplasmic reticulum density and in functional calcium stores in cultured
neurons. J Biol Chem 274: 21673–21678.
19. Lloyd-Evans E, Pelled D, Riebeling C, Bodennec J, de-Morgan A, et al. (2003)
Glucosylceramide and glucosylsphingosine modulate calcium mobilization from
brain microsomes via different mechanisms. J Biol Chem 278: 23594–23599.
20. Pelled D, Trajkovic-Bodennec S, Lloyd-Evans E, Sidransky E, Schiffmann R, et
al. (2005) Enhanced calcium release in the acute neuronopathic form of Gaucher
disease. Neurobiol Dis 18: 83–88.
21. Bygrave FL, Benedetti A (1996) What is the concentration of calcium ions in the
endoplasmic reticulum? Cell Calcium 19: 547–551.
22. Berridge MJ, Bootman MD, Lipp P (1998) Calcium–a life and death signal.
Nature 395: 645–648.
23. Ong DS, Mu TW, Palmer AE, Kelly JW (2010) Endoplasmic reticulum Ca2+
increases enhance mutant glucocerebrosidase proteostasis. Nat Chem Biol 6:
424–432.
24. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, et al. (2008) DrugBank:
a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36:
D901–906.
25. Gunther S, Kuhn M, Dunkel M, Campillos M, Senger C, et al. (2008)
SuperTarget and Matador: resources for exploring drug-target relationships.
Nucleic Acids Res 36: D919–922.
26. Ron D, Walter P (2007) Signal integration in the endoplasmic reticulum
unfolded protein response. Nat Rev Mol Cell Biol 8: 519–529.
27. Schroder M, Kaufman RJ (2005) The mammalian unfolded protein response.
Annu Rev Biochem 74: 739–789.
28. Gupta S, Deepti A, Deegan S, Lisbona F, Hetz C, et al. (2010) HSP72 protects
cells from ER stress-induced apoptosis via enhancement of IRE1alpha-XBP1
signaling through a physical interaction. PLoS Biol 8: e1000410.
29. Lin JH, Li H, Zhang Y, Ron D, Walter P (2009) Divergent effects of PERK and
IRE1 signaling on cell viability. PLoS ONE 4: e4170.
30. Oyadomari S, Mori M (2004) Roles of CHOP/GADD153 in endoplasmic
reticulum stress. Cell Death Differ 11: 381–389.
Remodeling Proteostasis in Gaucher Disease Cells
PLOS ONE | www.plosone.org 10 April 2013 | Volume 8 | Issue 4 | e61418
31. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR (2010) The BCL-
2 family reunion. Mol Cell 37: 299–310.
32. Xu SZ, Zhong W, Watson NM, Dickerson E, Wake JD, et al. (2008) Fluvastatin
reduces oxidative damage in human vascular endothelial cells by upregulating
Bcl-2. J Thromb Haemost 6: 692–700.
33. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal
storage disorders. JAMA 281: 249–254.
34. Dionisi-Vici C, Rizzo C, Burlina AB, Caruso U, Sabetta G, et al. (2002) Inborn
errors of metabolism in the Italian pediatric population: a national retrospective
survey. J Pediatr 140: 321–327.
35. Beutler E, Nguyen NJ, Henneberger MW, Smolec JM, McPherson RA, et al.
(1993) Gaucher disease: gene frequencies in the Ashkenazi Jewish population.
Am J Hum Genet 52: 85–88.
36. Wraith JE (2006) Limitations of enzyme replacement therapy: current and
future. J Inherit Metab Dis 29: 442–447.
37. Hoogerbrugge PM, Brouwer OF, Bordigoni P, Ringden O, Kapaun P, et al.
(1995) Allogeneic bone marrow transplantation for lysosomal storage diseases.
The European Group for Bone Marrow Transplantation. Lancet 345: 1398–
1402.
38. Ficicioglu C (2008) Review of miglustat for clinical management in Gaucher
disease type 1. Ther Clin Risk Manag 4: 425–431.
39. Lu J, Yang C, Chen M, Ye DY, Lonser RR, et al. (2011) Histone deacetylase
inhibitors prevent the degradation and restore the activity of glucocerebrosidase
in Gaucher disease. Proc Natl Acad Sci U S A 108: 21200–21205.
40. Termine DJ, Moremen KW, Sifers RN (2009) The mammalian UPR boosts
glycoprotein ERAD by suppressing the proteolytic downregulation of ER
mannosidase I. J Cell Sci 122: 976–984.
41. Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, et al. (2007) IRE1 signaling
affects cell fate during the unfolded protein response. Science 318: 944–949.
42. Kitamura M (2008) Endoplasmic reticulum stress and unfolded protein response
in renal pathophysiology: Janus faces. Am J Physiol Renal Physiol 295: F323–
334.
43. Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that
mediate cell death. Nat Rev Mol Cell Biol 9: 47–59.
44. Eckenrode EF, Yang J, Velmurugan GV, Foskett JK, White C (2010) Apoptosis
protection by Mcl-1 and Bcl-2 modulation of inositol 1,4,5-trisphosphate
receptor-dependent Ca2+ signaling. J Biol Chem 285: 13678–13684.
45. Rong YP, Bultynck G, Aromolaran AS, Zhong F, Parys JB, et al. (2009) The
BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the
regulatory and coupling domain of the IP3 receptor. Proc Natl Acad Sci U S A
106: 14397–14402.
Remodeling Proteostasis in Gaucher Disease Cells
PLOS ONE | www.plosone.org 11 April 2013 | Volume 8 | Issue 4 | e61418
